Broad antibody and T cell reactivity induced by a pneumococcal whole-cell vaccine

Vaccine

Volumn 30, Issue 29, 2012, Pages 4316-4322

  Moffitt, Kristin L ^a   Yadav, Puja ^a   Weinberger, Daniel M ^b   Anderson, Porter W ^a   Malley, Richard ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Colonization; IL 17; Sepsis; Serotype independence; Species common antigen; Streptococcus pneumoniae; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; BACTERIAL ANTIGEN; HUMORAL ANTIBODY; IMMUNOGLOBULIN BINDING FACTOR; IMMUNOGLOBULIN G; INTERLEUKIN 17; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LIBRARY; ARTICLE; ASPIRATION PNEUMONIA; BACTERIAL CELL WALL; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; BINDING AFFINITY; CELL ENCAPSULATION; CELL ISOLATION; CELLULAR IMMUNITY; CLINICAL EVALUATION; COISOGENIC STRAIN; CONTROLLED STUDY; DRUG ADSORPTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FATALITY; FLOW CYTOMETRY; GENE; GENETIC VARIABILITY; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; NASOPHARYNX; NONHUMAN; PRIORITY JOURNAL; RABBIT; SEROTYPE; SERUM; T LYMPHOCYTE; TH17 CELL;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, BACTERIAL; CROSS REACTIONS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INTERLEUKIN-17; MICE; MICE, INBRED C57BL; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RABBITS; TH17 CELLS;

EID: 84857975056     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.034     Document Type: Article

References (28)

1. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(September (9693)):893-902.
2. Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 378(April):1962-1973.
3. Moffitt K.L., Malley R. Next generation pneumococcal vaccines. Curr Opin Immunol 2011.
4. Liberman C., Takagi M., Cabrera-Crespo J., Sbrogio-Almeida M.E., Dias W.O., Leite L.C., et al. Pneumococcal whole-cell vaccine: optimization of cell growth of unencapsulated Streptococcus pneumoniae in bioreactor using animal-free medium. J Ind Microbiol Biotechnol 2008, 35(November (11)):1441-1445.
5. Lu Y.J., Leite L., Goncalves V.M., Dias Wde O., Liberman C., Fratelli F., et al. GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis. Vaccine 2010, 28(November (47)):7468-7475.
6. Malley R., Trzcinski K., Srivastava A., Thompson C.M., Anderson P.W., Lipsitch M. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci U S A 2005, 102(March (13)):4848-4853.
7. Lu Y.J., Gross J., Bogaert D., Finn A., Bagrade L., Zhang Q., et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog 2008, 4(September (9)):e1000159.
8. Lu Y.J., Yadav P., Clements J.D., Forte S., Srivastava A., Thompson C.M., et al. Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol 2010, 17(June (6)):1005-1012.
9. Weinberger D.M., Trzcinski K., Lu Y.J., Bogaert D., Brandes A., Galagan J., et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog 2009, 5(June (6)):e1000476.
10. Trzcinski K., Thompson C.M., Lipsitch M. Construction of otherwise isogenic serotype 6B, 7F, 14, and 19F capsular variants of Streptococcus pneumoniae strain TIGR4. Appl Environ Microbiol 2003, 69(December (12)):7364-7370.
11. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348(May (18)):1737-1746.
12. Cutts F.T., Zaman S.M., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005, 365(March-April (9465)):1139-1146.
13. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349(October (14)):1341-1348.
14. Croucher N.J., Harris S.R., Fraser C., Quail M.A., Burton J., van der Linden M., et al. Rapid pneumococcal evolution in response to clinical interventions. Science 2011, 331(January (6016)):430-434.
15. Hanage W.P. Serotype-specific problems associated with pneumococcal conjugate vaccination. Future Microbiol 2008, 3(February (1)):23-30.
16. Feavers I., Knezevic I., Powell M., Griffiths E. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada. Vaccine 2009, 27(Jun (28)):3681-3688.
17. Lu Y.J., Forte S., Thompson C.M., Anderson P.W., Malley R. Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide. Infect Immun 2009, 77(May (5)):2076-2083.
18. McDaniel L.S., Waltman W.D., Gray B., Briles D.E. A protective monoclonal antibody that reacts with a novel antigen of pneumococcal teichoic acid. Microb Pathog 1987, 3(October (4)):249-260.
19. Trzcinski K., Thompson C.M., Srivastava A., Basset A., Malley R., Lipsitch M. Protection against nasopharyngeal colonization by Streptococcus pneumoniae is mediated by antigen-specific CD4+ T cells. Infect Immun 2008, 76(April (6)):2678-2684.
20. Szu S.C., Schneerson R., Robbins J.B. Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci. Infect Immun 1986 Nov, 54(2):448-455.
21. Musher D.M., Watson D.A., Baughn R.E. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection?. J Infect Dis 1990, 161(4):736-740.
22. Briles D.E., Forman C., Horowitz J.C., Volanakis J.E., Benjamin W.H., McDaniel L.S., et al. Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun 1989 May, 57(5):1457-1464.
23. Skov Sorensen U.B., Blom J., Birch-Andersen A., Henrichsen J. Ultrastructural localization of capsules, cell wall polysaccharide, cell wall proteins, and F antigen in pneumococci. Infect Immun 1988 Aug, 56(8):1890-1896.
24. Plotkin S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010, 17(July (7)):1055-1065.
25. Huang S.S., Hinrichsen V.L., Stevenson A.E., Rifas-Shiman S.L., Kleinman K., Pelton S.I., et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 2009, 124(July (1)):e1-e11.
26. McCool T.L., Weiser J.N. Limited Role of Antibody in Clearance of Streptococcus pneumoniae in a Murine Model of Colonization. Infect Immun 2004, 72(October (10)):5807-5813.
27. Richards L., Ferreira D.M., Miyaji E.N., Andrew P.W., Kadioglu A. The immunising effect of pneumococcal nasopharyngeal colonisation; protection against future colonisation and fatal invasive disease. Immunobiology 2010, 215(April (4)):251-263.
28. Zhang Z., Clarke T.B., Weiser J.N. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 2009, 119(June (7)):1899-1909.